What is your background in treating psoriasis? What percentage of your cases do you consider moderate to severe? Are these numbers increasing over time?

 What do you like and dislike about current psoriasis drugs on the market? What do you consider the standard of care for moderate-severe psoriasis? Are there any new drugs, especially biologics, coming through the pipeline to be excited about? 

 What are your thoughts on brodamulab? What are your thoughts on the IL-17 mechanism of action? Does it make sense to you? Would you consider prescribing brodamulab based on the Phase 1-3 data? Do you think some form of brodamulab has the potential to treat less severe cases of psoriasis in the future?

What are your thoughts on the incidences of suicidal thoughts (4/3180) in the Phase 3 trials for brodamulab? Do these seem like unusually high numbers for psoriasis patients to you? What type of warning do you think the FDA is most likely to impose on a drug like this, if any?

What sort of outcome would you ultimately expect from the November PDUFA? Could you walk us through some of the most likely scenarios and how this would impact brodamulab's ability to perform in the psoriasis market?